Not Just A Tweak: UK Review Seeks Sea Change In Drug Development
This article was originally published in Scrip
The UK government's Accelerated Access Review is planning to bring big and meaningful changes to the way drugs are developed and brought to UK patients and is not just a tweak to the system. So says, Dr Stuart Dollow, chief executive and founder of Vermilion Life Sciences, who is helping to lead the review.
You may also be interested in...
International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.